Psychiatric Genotype/Phenotype Project Repository
Launched by VANDERBILT UNIVERSITY · Sep 29, 2008
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The links between psychiatric symptoms and underlying biological processes remain unclear at this time. Unipolar Major Depressive Disorder, Bipolar Disorder, and Schizophrenia are associated with major disruptions in functioning and quality of life. Understanding the causal physiological and genetic factors involved in each of these disorders would allow us to make great strides in tailoring treatment to the individual's needs. Because the etiology of these disorders are likely multifactorial in nature, a study examining a wide range of variables might best allow us to examine the interacti...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Between the ages of 16 and 65
- • 2. Able and willing to provide informed consent
- • 3. Able to read and speak English sufficiently to provide consent and answer questions
- 4. Diagnosis of one of the following:
- • Unipolar Major Depressive Disorder of any subtype
- • Bipolar I, Bipolar II Disorder, or Bipolar Disorder NOS
- • Axis I Psychotic Disorder, which can include the diagnoses of Schizophrenia, Schizoaffective Disorder, Major Depression or Mania with Psychotic Features, Schizophreniform Disorder, Brief Psychotic Episode, or Psychotic Disorder NOS
- • Normal volunteer controls, individuals with no personal history of any Axis I disorder.
- Exclusion Criteria:
- • 1. Reported pregnancy or breastfeeding
- • 2. Dementia or delirium
- 3. Any medical condition that would interfere with participation in the study. This would include, but not be limited to:
- • uncontrolled diabetes, hypothyroidism, Cushing's disease, or other significant endocrine condition (treated endocrine condition is allowed)
- • demyelinating disease
- • HIV infection
- • active hepatitis
- • CNS infection
- • clinically significant and unstable cardiovascular disease
- • any cancer involving the CNS (including metastatic disease)
- • 4. Exclusion criteria for normal control subjects include any history of mental illness or psychotropic drug abuse.
- • 5. Participants will be excluded from the imaging portion of the study if they have any condition deemed to interfere with PET or MRI scanning, such as but not restricted to extreme obesity, metal fragments in eyes, metal implants in the head, or cochlear implant. These participants may still take part in the portion of the study involving the clinical assessment and providing biological samples.
About Vanderbilt University
Vanderbilt University is a prestigious research institution renowned for its commitment to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on collaboration across various disciplines, Vanderbilt leverages its state-of-the-art facilities and a diverse team of experts to conduct rigorous clinical studies. The university is dedicated to improving patient outcomes by exploring novel therapeutic interventions and enhancing understanding of disease mechanisms. Through its robust clinical research infrastructure, Vanderbilt University aims to contribute significantly to the scientific community and the development of effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Patients applied
Trial Officials
Stephan Heckers, M.D.
Principal Investigator
Vanderbilt University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials